Preventive Hepatitis B Vaccine with a Short Duration Regimen
Hepatitis B infection is a major health concern worldwide, particularly in Asia and Africa. The World Health Organization estimates that 600,000 people die each year due to consequences of chronic hepatitis B infection such as cirrhosis and liver cancer, and approximately 40,000 die each year from the effects of acute infection. Current vaccines do not provide adequate protection to defined at-risk populations and require a three-dose regimen that limits broad accessibility.
The YS-HBV-001 is designed with PIKA technology as a new generation of hepatitis B vaccine with two doses over one month to replace the existing 3 doses over 6 months of conventional vaccines. Early stage clinical studies have demonstrated comparable immune response of YS-HBV-001 delivered in three doses over one month as compared with the standard vaccine in a three-dose, six month regimen. YS-HBV-001 also demonstrated its capability of stimulating higher levels of antibody production as well as more robust and lasting T cell response.